FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.
What happened
FDA inspected Neobiosis’s Gainesville, Florida facility from January 23, 2023, to February 21, 2023. FDA found the company was distributing amniotic fluid and umbilical cord products without approved biologics licenses or investigational new drug applications, based partly on social media and interviews promoting wound healing and orthopedic uses. The inspection also found significant CGMP deviations, including unvalidated aseptic processing and inadequate environmental monitoring for products purported to be sterile.
What FDA found
The company sold amniotic fluid and umbilical cord products as drugs or biologics without an FDA-approved license or an investigational new drug application in effect.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. § 331(d), § 355(a)]; PHS Act section 351(a)(1) [42 U.S.C. § 262(a)(1)]The umbilical cord products did not meet FDA’s criteria for cells and tissues regulated only under its tissue rules, because they were promoted for non-natural uses and were more than minimally processed.
21 CFR 1271.10(a)(1)-(2); 21 CFR 1271.3(c), (f)(1)The company had not validated the aseptic processes or equipment sterilization used for products that purport to be sterile.
21 CFR 211.113(b)The company had inadequate environmental monitoring and had not validated cleaning and disinfection for the aseptic processing areas and equipment.
21 CFR 211.42(c)(10)(iv)-(v)The company had not validated its manufacturing and reprocessing processes and lacked adequate final product specifications for identity, strength, quality, and purity.
21 CFR 211.100(a); 21 CFR 211.160(b)The company assigned a two-year expiration date without an adequate stability testing program to support storage conditions and expiration.
21 CFR 211.166(a)
What FDA wants
FDA asks Neobiosis to respond in writing within 15 working days with specific corrective steps and supporting documentation, and to address remaining in-house inventory, product already distributed that is still within its labeled expiry, and plans for BLAs or INDs.
Who should pay attention
- clinics and physicians buying amniotic or umbilical cord products
- distributors and brand owners of regenerative medicine products
- contract manufacturers making sterile biologics or tissue-based products
This is a summary. Read the original letter on fda.gov.